BRIEF — Horizon Discovery in deal with US I-O company

Horizon Discovery (LSE: HZD), a specialist in gene editing and gene modulation technologies, has entered into a non-exclusive out-licensing agreement with a USA-based immuno-oncology therapeutics developer.

Under the terms of the agreement, Horizon has licensed to the partner a novel cell line engineering technology as well as non-exclusive rights to its proprietary Helitron transposon gene editing technology for an undisclosed financial consideration.

Horizon’s provision of translational genomics tools and services for companies seeking to empower personalized medicine programs have made the company  one of the biggest names in life sciences in the UK, and it is now becoming a profit-making enterprise too.

Darrin Disley, chief executive, said: "This agreement demonstrates the impact of this approach and the value of licenses to our novel technologies, and we anticipate this becoming a significant additional revenue stream for the group going forward."